LeserbriefKommentar
Intrapartum Azithromycin vs Placebo for Neonatal Sepsis
JAMA · 2023
DOI: 10.1001/jama.2023.8328 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2023. Verfasst von Wan-Jie Gu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit, First Affiliated Hospital of Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Azithromycin, Neonatal Sepsis, Anti-Bacterial Agents. Die Arbeit nennt 5 Literaturangaben.
Themen: Sepsis
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
AzithromycinNeonatal SepsisAnti-Bacterial AgentsHumansInfant, NewbornFemalePregnancyPeripartum Period
Substanzen
AzithromycinAnti-Bacterial Agents
Autor:innen und Institutionen
- Department of Intensive Care Unit, First Affiliated Hospital of Jinan University, Guangzhou, China.
- Department of Clinical Research, First Affiliated Hospital of Jinan University, Guangzhou, China.
Zitieren
APA
Gu, W. J., Lyu, J., & Yin, H. Y. (2023). Intrapartum Azithromycin vs Placebo for Neonatal Sepsis. JAMA. https://doi.org/10.1001/jama.2023.8328
Vancouver
Gu WJ, Lyu J, Yin HY. Intrapartum Azithromycin vs Placebo for Neonatal Sepsis. JAMA. 2023. doi:10.1001/jama.2023.8328
BibTeX
@article{Gu2023,
author = {Gu, Wan-Jie and Lyu, Jun and Yin, Hai-Yan},
title = {Intrapartum Azithromycin vs Placebo for Neonatal Sepsis},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.8328}
}
EUVIMED